gucci pas cher

sacoche gucci

sac femme pas cher

sac gucci pas cher

gucci sac

sac gucci

lancel soldes

lancel pas cher

sac lancel bb

sac prada

sac longchamp pas cher


lunette de soleil ray ban

sac lancel

lancel pas cher

barbour jacket

barbour uk

barbour by mail

barbour wax jacket

barbour international jacket

mens barbour jacket

christian louboutin pas cher

sac celine

sac chanel pas cher

sac hermes

louis vuitton pas cher

christian louboutin outlet

louis vuitton belt

gucci mens belt

timberland boots outlet

beats by dre

christian louboutin outlet

´╗┐barbour jacket

barbour jacket barbour outlet barbour jacket sale barbour uk barbour wax jacket cheap barbour jackets sac lancel lancel soldes lancel pas cher sac lancel bb lancel adjani barbour jacket barbour by mail barbour wax jacket barbour uk barbour coats sac lancel bb sac lancel pas cher lancel pas cher lancel brigitte bardot barbour sale Barbour international jacket barbour jackets women barbour by mail barbour shop london barbour jackets barbour sale


Antibiotic-resistant bacterial pathogens have been a rising threat to human health for several years. Effectiveness of many antibacterial agents has declined worldwide limiting physicians' options to treat serious infections. Antibiotic drug resistance has a significant impact on morbidity and mortality and contributes heavily to healthcare system costs worldwide. The World Health Organization has stated that antibiotic resistance is one of the greatest healthcare challenges for the future.

Cempra is focused on developing differentiated antibiotics to confront the rising threat of antibiotic-resistant pathogens. Two products are in clinical development. Solithromycin is a novel, orally- and intravenously-active, broad-spectrum fluoroketolide. It is currently in a Phase III clinical trial in patients with moderate to moderately-severe coummunity-acquired bacterial pneumonia. A Phase I trial for the intravenous formulation is ongoing. Single-dose oral administration of solithromycin was tested in patients with uncomplicated gonorrhea in a Phase II clinical trial. TAKSTA™ (CEM-102, sodium fusidate) is an innovative dosing regimen of a product with a long history of safety and efficacy outside the U.S. against gram-positive organisms including MRSA. We have completed a Phase II trial in acute bacterial skin and skin structure infections and we initiated a Phase II clinical trial in patients with prosthetic joint infections.